Can-C Eyedrops
(N-acetylcarnosine)

We sell the original Can-C eye-drop used in the clinical trials by IVP and Dr. Mark Babizhayev. IVP maintains that only the original unadulterated formula is effective in reducing, reversing and slowing the occurrence of senile cataract.

• Can-C has been proven to reduce the occurrence and slow the development of senile cataract.
• Can-C is also beneficial for contact lens disorders.
• Can-C has been shown to help those suffering from presbyopia.
• Can-C can be used to treat corneal disorders.
• Can-C can combat eyestrain.
• Can-C can ease computer vision syndrome.
• Can-C can end the discomfort of ocular inflammation.
• Can-C can restore normal sight to those inflicted with blurred vision.
• Can-C can alleviate dry eye syndrome.
• Can-C has been used with great success in the fight against retinal diseases.
• Can-C has been used in the treatment of vitreous opacities and lesions.
• Can-C has a wealth of properties which can improve the function of the aging eye.

Using Can-C

Can-C has been shown to have measurable affects within only 1-month!

The Can-C itself is produced by a pharmaceutical company and then packaged by an FDA approved ophthalmic facility. The product is housed within a labelled and printed 6.4cm x 4.4cm x 3.2cm box. Each box contains 5 x 2ml re-sealable vials, along with an insert that explains how the vials are opened, used and sealed etc.

It is recommended that for maximum efficacy, administration be continued for a period of not less than 3-5 months. As most of the clinical trials have been measured at 3 and 6 month periods, a period of 6-months should be considered.

Treatment dosages are at 1 or 2 drops, twice a day. Once an individual 2ml vial is opened it must be stored in a fridge and used within 21-days (or 3-weeks). Each 2ml vial contains approximately 30-drops; this means that each 2ml vial will last for approximately 7-8 days at 4-drops per day, or 15 days at 2-drops per day. As a box contains 5 x 2ml vials, each package can last between 35 and 75 days.

Unopened vials can be stored at room temperature, but it is recommended, that for long-term storage the vials should be kept in a fridge at 2 to 8 degrees Celsius. We do not recommend freezing. Note that unopened vials are good for up to 24 months, from the date of manufacture.

Can-C may be required on a regular basis to help maintain the eye's natural anti-oxidant defences and therefore help to prevent a re-appearance of senile cataract and other eye degenerative disorders. As a preventative measure, 1-drop into the eye once a day with frequent breaks may be a suitable on-going regime.

As usual with most treatments, the earlier one starts the better the results that can be expected. In the clinical trials, persons who had cataracts less than 7-years have the fastest and greatest results. Persons with cataract from 7-15 years still have good results. Only persons who had maintained cataracts for more than 15-years have the least results, although even then they still managed to obtain improvements.

Can-C must NOT be used orally. Until more is understood about N-acetylcarnosine and its oral use in humans, this route of administration must be avoided. However, Can-C has been shown to be safe and effective for humans when used as an eye-drop or as an intra-nasal spray.

With the correct material and formula, in human clinical trials, there have been no reported side effects or contraindications, even when used everyday for up-to 2-years

N-acetylcarnosine is a temperamental molecule and other ingredients can impede its action and even break it down, therefore reducing its effectiveness. As such, combinations of "other" ingredients with N-acetylcarnosine shouldn't be taken for granted, and should not be automatically added without further investigation and research etc. For example, hydrophobic compounds such as vitamin A and vitamin E have branched hydrocarbon skeletons that inhibit the activity of N-acetylcarnosine, particularly in the cornea and conjunctiva of the eye. Recent evidence with vitamin E, shows us that its combination with N-acetylated compounds abolished the potential of the entire mixture.

Expert Opinion

Senile cataract is the most commonly performed surgical operation in the world today; some 26,000 people each year, in the United States alone are diagnosed with senile cataract each day. There are 1.35 million eye operations each year in the USA and 2% of them (or 27,000 individuals) develop serious complications as a result of cataract surgery.

Can-C eye-drops have been shown to help reduce, reverse and slow the occurrence of senile cataract.

Senile cataract is caused by the nuclear matter of the elderly human lens hardening and taking on a yellowish/brown color. Once this occurs there is obvious vision impairment and deterioration.

This hardening and discoloration of the lens is the result of lifelong cross-linking (or glycosylation), of the lens proteins with ascorbate. This persists in the aqueous humor at high concentrations, due to the kynurenine derivatives, and takes place due to the low availability of natural defenses in the form of anti-oxidants, (which decline with advancing age).

Can-C contains N-acetylcarnosine which is a di-peptide, (that's two amino acids linked together). The particularly pure form is known as n-alpha-acetylcarnosine.

As you can imagine this is a complex subject. But essentially, N-acetylcarnosine is a "carrier" for the di-peptide L-carnosine into the aqueous humor of the eye, (this is the fluid area surrounding the lens).

It is here, that the substance becomes most active in its ability to basically act, as a natural and comprehensive anti-oxidant. Once N-acetylcarnosine has delivered L-carnosine safely through into the aqueous humor, the L-carnosine itself is flushed out of the eye via the canal of schlemm, and once into the bloodstream, it is broken down by carnosinase and excreted. N-acetylcarnosine is acting as a time release version of carnosine resistant to hydrolysis with carnosinases.

The major role of N-acetylcarnosine and L-carnosine is their facility to act in the biological system as universal antioxidants. They possess the ability to protect cells from oxidative stress, both in the lipid phase of cellular membranes and in the aqueous environment. L-carnosine is able to reduce the content of lipid peroxidation products in the peroxidized lens fiber cells plasma membranes, and to repair their structure accordingly. It is the only known anti-oxidant able to protect structural proteins of the lens/alpha-crystalline, from the free-radical induced oxidation process.

The statistics in the human trials show that Can-C eye-drops applied for 6-months, (twice daily into the eye), in patients all suffering from senile cataract, had the following results:

1. 88.9% had an improvement of glare sensitivity.

2. 41.5% had an improvement of the transmissivity of the lens.

3. 90% had an improvement in visual acuity.

Animal Trials

The testing of various anti-glycaytion agents over nearly a decade led a Russian research team to the development of n-alpha-acetylcarnosine as a delivery system for the natural eye anti-oxidant of L-carnosine. Once laboratory testing was passed, the next stage began to test the n-acetylcarnosine eye-drops in the eyes of animals, (specifically canines and rabbits). These studies produced remarkably fast results in the improvement of clarity, glare sensitivity and overall vision for the animals involved. Furthermore, no serious side effects were noted and the beneficial affects were sustainable. Unsurprisingly, these positive results in animals led to the studies being continued in humans.

Human Trials

Carnosine eye-drops were used in a clinical trial to treat 96 patients aged 60 and above. All the patients had senile cataract in various degrees of maturity. The duration of the disease in these patients ranged between 2 and 21 years. The patients instilled 1 or 2 drops into each eye 3 or 4 times a day, for a period of 3 to 6 months.

The results showed that there was a pronounced effect on senile cataract, the rate was 100% (i.e. all patients experienced an improvement). For the more mature senile cataract the effective rate was still an extremely impressive 80%. Importantly, it was also noted that there were no side effects in any of the cases. Another Russian study was designed to document and quantify the changes in lens clarity over a 6 to 24 month period. Their average age was 65 and all suffered from senile cataract of a minimal to an advanced opacification.

The patients received either a 1% solution of N-acetylcarnosine eye-drops or a placebo as 2-drops twice a day into each eye. The results at 6 months were impressive; 88.9% of all eyes treated with N-acetylcarnosine had an improvement of glare sensitivity. Furthermore, 90% of the eyes treated with N-acetylcarnosine showed an improvement in visual acuity. In contrast, there was little change in the eye quality of the placebo group at 6 months and the placebo group also experienced a gradual deterioration at 12 to 24 months.

Another study evaluated patients who had various degrees of eyesight impairment but who did not have the symptoms of cataract. After a course of treatment ranging from 2 to 6 months the conclusion was that the eye-drops alleviated eye tiredness and continued to improve eyesight (i.e. there was more clear vision). This is an indicator that the eye-drops have a value both for preventative purposes as well as medical applications.

Cataract surgery is the most commonly performed surgery in the world today. It numbers 1.35 million yearly in the U.S. alone. A little known fact though is that this most common surgery also can have serious complications which annually affect 2% (27,000 individuals). Added to this are the fears and discomforts associated with surgery and the potential problems resulting from an artificial lens including restricted usage. Thankfully, there is an alternative.

Can-C eye drops patented by Innovative Vision Products (IVP) contain 1% solution n-alpha-acetyl-carnosine and are sold strictly as an “eye lubricant,” have been heralded as a breakthrough in the treatment and prevention of senile cataract. The drops have been shown to slowly help reverse, reduce and slow the occurrence of senile cataract. They show a significant clinical success rate within 3-12 months of treatment with measurable results that can occur in as little as one month especially in the cases of red eye and night vision.

Besides help for cataract, Mark Babizhayev, one of the principal Russian researchers behind the development and use of N-alpha-acetyl-carnosine (NAC) eye-drops, feels the drops may also help other eye conditions. Unpublished information indicates the unique lubricant formula may benefit open-angle primary glaucoma (when used with beta-blockers). Additionally, it is believed to address presbyopia (old age vision), corneal disorders and retinal diseases, computer vision syndrome, eye strain, ocular inflammation, blurred vision, dry eye syndrome, vitreous opacities and lesions as well as complications of diabetes mellitus and other systemic diseases. Also, Can-C can help to make contact lenses more comfortable. It is also thought that the NAC has the ability to reduce lactic acid (protein) buildup in the eye to allow lenses to be safely worn for longer periods of time.

Can-C works by fighting the effects of gylcation (the cross linking of proteins with glucose and oxygen) directly within the eye. Glycation is one of the many destructive processes that contribute to aging. Can-C is believed to slow and help prevent proteins from cross-linking and becoming a cataract. It is also felt that n-alpha-acetyl-carnosine breaks cross-links to help dissolve existing cataracts. NAC is a universal antioxidant that is active against potent free radicals.

Usual dosages are 1 or 2 drops, twice daily, continued for not less than 3-5 months for maximum efficiency. Since most clinical trials have been measured at 3- and 6-month periods, a 6-month period should be considered, suggests one expert. Please note that if using in both eyes the dosage could be lessened due to synergistic ocular cross over. The drops are used as a preventive measure against many aging eye disorders and to combat existing eye ailments.

Please see product insert for administration directions. Some people find they have a temporary stinging sensation common with many eye drops. These drops are as close to the average ph level of the eye as possible but of course some people are more sensitive to certain products than others.

Important: L-carnosine and N-alpha-acetyl-carnosine (NAC), while chemically related, are very different. L-carnosine cannot be used topically in the eye since it would release histamine, a toxic compound which would create eye-problems in long-term use. Conversely, NAC or Can-C must not be used orally because it is not absorbed from the gastrointestinal tract and when taken over time, it can release histamine into the intestines.

Another factor to consider are the added ingredients in an n-acetylcarnosine formula. N-acetylcarnosine is a temperamental molecule. Added ingredients, e.g., vitamin A or E, can inhibit the activity of N-acetylcarnosine. Worse yet, some added ingredients can cause negative side effects.

The easiest way to be sure the material and formula are the correct type is look for Innovative Vision Products on the label. You will find n-alpha-acetylcarnosine in the ingredient list—the NAC used in the human trials containing the exact formulation for maximum safety. Brite Eyes and other imitation products are not endorsed by IVP and therefore do not contain the correct formula as used in the clinical trials. Buyer Beware!

Statement: This product is manufactured in accordance with the requirements as set forth by the Food and Drug Administration monograph for ophthalmic products. The statements contain herein have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Important statement of fact by the leading researcher of the Can-C eye drops.

Approved Uses

© IAS Ltd.